Overview

Procuring a 105-gene next-generation sequencing panel for lung cancer means matching laboratory capacity with the biomarker demands of modern thoracic oncology. NCCN guidelines recommend that advanced non-small-cell lung cancer undergo broad molecular profiling that includes EGFR, ALK, ROS1, BRAF, MET exon 14, RET, ERBB2, KRAS G12C, and NTRK fusions, alongside PD-L1 assessment. A panel of this breadth supports a single-test workflow that can surface multiple actionable drivers at once, which matters for distributors and reference labs serving hospitals that want to consolidate send-out testing. The sourcing decision should start from the clinical questions the lab must answer, then map them to gene content, wet-lab method, and the reporting format clinicians expect to receive.

What the Panel Covers

A 105-gene configuration typically pairs DNA sequencing for point mutations and copy-number changes with RNA or fusion-optimized methods for rearrangements. Coverage of the guideline-listed drivers plus tumor mutational burden and microsatellite status gives oncologists a consolidated result instead of several separate assays. For buyers, the practical question is whether the vendor's gene list actually includes the NCCN minimum set and reports it in a way that maps to approved targeted therapies. Requesting a sample report is the fastest way to confirm the panel addresses both common alterations such as EGFR exon 19 deletions and rarer events such as MET exon 14 skipping, and that the variant interpretation is written for a tumor board rather than a research audience.

Procurement and Logistics Factors

Accreditation is the first filter: laboratories running these tests should operate under CAP, CLIA, or ISO 15189 frameworks, because results inform treatment selection. Sample logistics follow close behind, since most panels accept formalin-fixed paraffin-embedded tissue while plasma circulating tumor DNA offers a liquid-biopsy alternative when tissue is scarce. Confirm cold-chain and transit expectations with the supplier, plus the minimum tumor content the assay requires, since low cellularity can trigger a reflex recommendation. Turnaround and bioinformatics support, including variant interpretation and a structured clinical report, determine whether the service fits a busy oncology pathway or merely adds another step before the patient starts therapy.

FAQ

Q: Does a 105-gene panel replace separate PD-L1 testing? A: Not usually. PD-L1 is measured by immunohistochemistry on a different platform, so most workflows pair the NGS report with a separate PD-L1 result to guide immunotherapy decisions.

Q: What sample types can the panel accept? A: Formalin-fixed paraffin-embedded tissue is standard, and plasma-based circulating tumor DNA is accepted by many vendors as a reflex or alternative when tissue is limited.

Q: Which accreditations should a supplying lab hold? A: CAP, CLIA, or ISO 15189 recognition indicates the laboratory meets quality standards for tests that directly inform therapy selection.